

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10570849	
	Filing Date		2006-03-06	
	First Named Inventor	Jamal Tazi		
	Art Unit	1761		
	Examiner Name	Not Yet Assigned		
	Attorney Docket Number	REGIM 3.3-085		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	2002018768		2002-02-14	Kerem	

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0 010 029	EP		1980-04-16	Anvar	English equivalent is US 4,434,290.	<input checked="" type="checkbox"/>
	2	0 317 416	EP		1989-05-24	Centre Nat Rech Scient	English equivalent is US 4,966,971	<input checked="" type="checkbox"/>
	3	92/09602	WO		1992-06-11	Rhone Poulenc Rorer Sa		<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10570849
Filing Date	2006-03-06
First Named Inventor	Jamal Tazi
Art Unit	1761
Examiner Name	Not Yet Assigned
Attorney Docket Number	REGIM 3.3-085

4	2 665 162	FR		1992-01-31	Univ Caen		<input checked="" type="checkbox"/>
5	5-310736	JP		1993-11-22	Tanabe Seiyaku Co		<input checked="" type="checkbox"/>
6	01/66129	WO		2001-09-13	Max Planck Gesellschaft et al.		<input type="checkbox"/>
7	0394112	EP		1990-10-24	Inst Nat Sante Rech Med		<input checked="" type="checkbox"/>
8	2387229	FR		1978-11-10	Anvar	English equivalent is US 4,266,060	<input checked="" type="checkbox"/>
9	2485537	FR		1981-12-31	Anvar	English equivalent is US 4,444,776.	<input checked="" type="checkbox"/>
10	2627493	FR		1989-08-25	Sanofi Sa		<input checked="" type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T's
	1	TAZI J ET AL. "DNA topoisomerase I: customs officer at the border between DNA and RNA worlds?" JOURNAL OF MOLECULAR MEDICINE (BERLIN, GERMANY) 1997 NOV-DEC. vol. 75, no. 11-12, november 1997 (1997-11), pages 786-800.	<input type="checkbox"/>
	2	PODDEVIN B ET AL. "DUAL TOPOISOMERASE I AND II INHIBITION BY INTOPLICINE (RP-60475), A NEW ANTITUMOR AGENT IN EARLY CLINICAL TRIALS" MOLECULAR PHARMACOLOGY, BALTIMORE, MD, U.S., vol. 44, no. 4, 1 october 1993 (1993-10-01), pages 767-774.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10570849
Filing Date	2006-03-06
First Named Inventor	Jamal Tazi
Art Unit	1761
Examiner Name	Not Yet Assigned
Attorney Docket Number	REGIM 3.3-085

3	PILCH B ET AL: "Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506" CANCER RESEARCH 15 SEP 2001 UNITED STATES, vol. 61, no. 18, 15 september 2001 (2001-09-15), pages 6876-6884.	<input type="checkbox"/>
4	SNYDER A L ET AL: "INHIBITION OF THE PROCESSING OF RIBOSOMAL PRECURSOR RNA BY NTERCALATING AGENTS" JOURNAL OF MOLECULAR BIOLOGY, vol. 58, no. 2, 1971, pages 555-565.	<input type="checkbox"/>
5	KENNEDY G D ET AL: "PREPARATION AND NUCLEIC ACID BINDING OF ELLIPTICINE DERIVATIVES" HETEROCYCLIC COMMUNICATIONS, FREUND PUBLISHING HOUSE, TEL AVIV, IL, vol. 2, no. 2, 1996, pages 125-128.	<input type="checkbox"/>
6	PENG YANHUA ET AL: "Rescue of mutant p53 transcription function by ellipticine." ONCOGENE, vol. 22, no. 29, 17 July 2003 (2003-07-17), pages 4478-4487.	<input type="checkbox"/>
7	KANSAL V K ET AL: "THE BIOGENETIC SYNTHETIC AND BIOCHEMICAL ASPECTS OF ELLIPTICINE AN ANTITUMOR ALKALOID" TETRAHEDRON, vol. 42, no. 9, 1986, pages 2389-2408.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.